Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock Price Down 1.7% – Time to Sell?

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) fell 1.7% on Friday . The company traded as low as $1.19 and last traded at $1.19. 980,573 shares were traded during trading, a decline of 15% from the average session volume of 1,148,093 shares. The stock had previously closed at $1.21.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on LCTX. D. Boral Capital reissued a “buy” rating and set a $3.00 target price on shares of Lineage Cell Therapeutics in a research note on Monday, May 4th. Canaccord Genuity Group initiated coverage on Lineage Cell Therapeutics in a research note on Tuesday, April 28th. They set a “buy” rating and a $9.00 price objective on the stock. HC Wainwright reissued a “buy” rating and set a $9.00 price target on shares of Lineage Cell Therapeutics in a research report on Tuesday, March 24th. Finally, B. Riley Financial lifted their target price on Lineage Cell Therapeutics from $3.00 to $4.00 and gave the stock a “buy” rating in a research note on Wednesday, March 25th. Four investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $6.25.

Lineage Cell Therapeutics Price Performance

The stock’s 50-day moving average price is $1.43 and its 200-day moving average price is $1.61. The company has a market cap of $296.67 million, a P/E ratio of -4.10 and a beta of 1.53.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.03) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.01). Lineage Cell Therapeutics had a negative return on equity of 89.36% and a negative net margin of 434.44%.The firm had revenue of $1.73 million for the quarter, compared to the consensus estimate of $3.60 million. As a group, analysts expect that Lineage Cell Therapeutics, Inc. will post -0.07 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. SG Americas Securities LLC bought a new position in shares of Lineage Cell Therapeutics in the fourth quarter worth about $25,000. Jump Financial LLC bought a new stake in shares of Lineage Cell Therapeutics during the 2nd quarter valued at approximately $28,000. DLD Asset Management LP acquired a new position in Lineage Cell Therapeutics during the 4th quarter worth approximately $33,000. Define Financial LLC bought a new position in Lineage Cell Therapeutics in the 4th quarter valued at approximately $33,000. Finally, Qube Research & Technologies Ltd acquired a new stake in Lineage Cell Therapeutics in the second quarter valued at approximately $35,000. Institutional investors own 62.47% of the company’s stock.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, allogeneic cell therapies built on pluripotent stem cell platforms. The company focuses on three primary therapeutic areas—retinal disease, neural repair and immune-effector cell oncology—leveraging its proprietary manufacturing processes to create off-the-shelf cell therapy candidates designed for broad patient populations.

Its lead candidate, OpRegen, comprises retinal pigment epithelium cells intended to slow or reverse vision loss in patients with geographic atrophy secondary to age-related macular degeneration.